
Loading, please wait...

Loading, please wait...

The TOGETHER study was a phase 2, randomized, participant- and investigator-blind, placebo-controlled trial of bepranemab, a humanized IgG4 monoclonal antibody targeting a mid-region epitope of tau. It enrolled 466 participants aged 50–80 years with prodromal-to-mild Alzheimer's disease (NIA-AA stage 3/4) and confirmed amyloid pathology, who received bepranemab 45 mg/kg, bepranemab 90 mg/kg, or placebo intravenously every 4 weeks over 80 weeks. The primary endpoint, change in CDR-Sum of Boxes at week 80, was not met for either dose. On the secondary endpoint ADAS-Cog14, both doses were associated with less cognitive decline than placebo, and bepranemab slowed tau accumulation on tau-PET in key brain regions. In participants with low baseline tau and in APOE ε4 non-carriers, high-dose bepranemab was associated with slower decline on CDR-SB and ADAS-Cog. Adverse events were similar between bepranemab and placebo, with no serious adverse events attributed to the drug. The findings support further evaluation of mid-region tau targeting in Alzheimer's disease.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The TOGETHER study was a phase 2, randomized, participant- and investigator-blind, placebo-controlled trial of bepranemab, a humanized IgG4 monoclonal antibody targeting a mid-region epitope of tau. It enrolled 466 participants aged 50–80 years with prodromal-to-mild Alzheimer's disease (NIA-AA stage 3/4) and confirmed amyloid pathology, who received bepranemab 45 mg/kg, bepranemab 90 mg/kg, or placebo intravenously every 4 weeks over 80 weeks. The primary endpoint, change in CDR-Sum of Boxes at week 80, was not met for either dose. On the secondary endpoint ADAS-Cog14, both doses were associated with less cognitive decline than placebo, and bepranemab slowed tau accumulation on tau-PET in key brain regions. In participants with low baseline tau and in APOE ε4 non-carriers, high-dose bepranemab was associated with slower decline on CDR-SB and ADAS-Cog. Adverse events were similar between bepranemab and placebo, with no serious adverse events attributed to the drug. The findings support further evaluation of mid-region tau targeting in Alzheimer's disease.
Today

A national cross-sectional survey reveals marked disparities in infectious disease diagnostic capacity across hospital tiers, underscoring the urgent need for integrated referral networks and enhanced point-of-care testing to improve outbreak detection and patient outcomes.
Today

The GESS-AEEM consensus establishes a clear clinical implementation framework for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder, focusing on transdermal dosing, precise laboratory monitoring, and safety communication.
Yesterday

A rare case of an asymptomatic left ventricular hemangioma highlights the vital role of multimodal imaging in differentiating vascular tumors from thrombus. Complete surgical resection under transesophageal echocardiography guidance prevents thromboembolism and delivers optimal outcomes.
Today

A landmark study evaluates long-term quality of life in adolescents and adults with brachial plexus birth injury. Severe functional limitation and limited access to care significantly worsen outcomes, underscoring the urgent need for persistent, multidisciplinary management across adult healthcare transitions.
Today

An analysis of 1,000 posts by macro- and mega-influencers on Instagram and TikTok revealed that 78.5% contained nutrition misinformation, while only 24% of creators held valid credentials. This article examines the clinical risks of viral dietary fads and provides actionable guidance for healthcare professionals.
Today